Kite, a Gilead Company, has signed a research collaboration agreement with Oxford BioTherapeutics (OBT).

The collaboration is set to evaluate five novel targets for a number of haematologic and solid tumour indications, according to a press release issued yesterday. The novel drug targets, already identified using OBT’s OGAP discovery platform, will be validated by the Oxford, UK-based oncology specialist as part of the Kite collaboration. Source: PM Live 7/1/2021